Categories: NewsPharmaceutical

Oculis updates share capital for its existing at-the-market offering program

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 2,500,000 ordinary shares of the Company (the “New Shares”), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 48,943,700, of which approximately 43 million shares are outstanding. Following the issuance, the number of treasury shares (own shares) held by the Company is 7.2% of the Company’s registered shares.

The New Shares were issued in relation to the sales agreement between the Company and Leerink Partners LLC (”Leerink Partners”)  entered into on May 8, 2024, with respect to an at-the-market (“ATM”) offering program. Under the ATM offering program, the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The New Shares have not been sold under the ATM offering program and will be held in reserve as treasury shares.

For more details on the ATM offering program, please refer to the Company’s previous press release dated May 17, 2024, and the Company’s SEC filings referenced therein.

For more information, please visit:
http://www.oculis.com

Oculis Contact:

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

Investor & Media Relations:

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com 

1-212-915-2577

Staff

Recent Posts

Community Hospital of Anaconda Notifies Individuals of Data Security Incident

ANACONDA, Mont., May 19, 2025 /PRNewswire/ -- Community Hospital of Anaconda ("CHA") is providing notice…

5 hours ago

Teal Health Announces Publication of SELF-CERV Study Results in JAMA Network Open Following FDA Approval of Teal Wand™ for At-Home HPV Screening

SAN FRANCISCO, May 19, 2025 /PRNewswire/ -- Following its recent FDA approval, Teal Health® announced the…

5 hours ago

BI2 Technologies and Support Our Sheriffs Foundation partner with SingleCare to create Sheriff Rx

Free program will provide access to affordable medications to Sheriffs' employees across the nation PLYMOUTH,…

5 hours ago

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

Collaboration Blends Advanced Cloud Technologies, Open-Source Collaboration, and Data Science Integration to support UCB's development pipeline…

5 hours ago

Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12M Series A Funding

AI-driven robotics platform reduces drug formulation development time from years to months SACRAMENTO, Calif., May…

5 hours ago

United Imaging Emphasizes Differentiated Technology at ISMRM 2025

Among the highlights were a completely unique whole-body 8 ch-parallel transmit coil on the 5T…

5 hours ago